What These Drugs Actually Are — and Why Everyone Is Talking About Them

When I first started seeing headlines about GLP-1 medications, the story seemed simple. These drugs were being described as a revolutionary breakthrough for weight loss. Celebrity interviews, wellness influencers, and breathless news segments presented them almost like a modern medical miracle. Within a short time, the conversation expanded. Suddenly the same medications were being discussed as potential treatments for addiction, binge eating, compulsive behavior, depression, anxiety, and even attention-related conditions.

That is usually the moment when I slow down and start asking questions.

Whenever a single class of medication is promoted as a possible solution for a wide range of human problems, skepticism becomes not only reasonable but necessary. Medical history contains many examples of treatments that appeared revolutionary during their early popularity yet later proved to be far more limited in their usefulness. That does not mean the current excitement surrounding GLP-1 medications is unfounded. Some of the research is genuinely intriguing. Yet the gap between scientific evidence and cultural enthusiasm has already become wide enough that it deserves careful examination.

This series begins with the most basic question: what are these drugs, and what are they actually approved to do in the United States?

Understanding that foundation matters. Without it, discussions about addiction, mental health, or broader behavioral effects quickly become distorted by misunderstandings about how the medications work and what scientists have actually demonstrated.

The Biology Behind the Acronym

GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the human body. It belongs to a class of hormones known as incretins, which are released by the intestines after food is consumed. These hormones help regulate blood sugar levels by signaling the pancreas to release insulin when glucose enters the bloodstream.

In simple terms, GLP-1 plays several key roles in metabolism.

It stimulates insulin release in response to food intake.

It suppresses glucagon secretion, which prevents the liver from releasing excessive glucose.

It slows the emptying of the stomach.

It sends signals to the brain that contribute to feelings of fullness.

The last two effects are particularly important for understanding why these medications became associated with weight loss. When stomach emptying slows and satiety signals increase, people tend to feel full sooner and remain full longer after eating.

Scientists began exploring ways to harness this hormonal system in the early 2000s. Researchers developed medications that mimic or enhance the activity of natural GLP-1 in the body. These drugs are known as GLP-1 receptor agonists, meaning they activate the same cellular receptors that natural GLP-1 would normally stimulate.

Originally, the goal was not weight loss. The goal was improved blood sugar control in people with type 2 diabetes.

The Medications in the GLP-1 Family

Several medications now fall into the broader GLP-1 category. Although they are often discussed as though they are interchangeable, they have important differences in structure, mechanism, and approved uses.

Semaglutide has become the most widely recognized member of the class. It appears in three major products.

Ozempic is approved for the treatment of type 2 diabetes.

Wegovy is approved for chronic weight management in adults with obesity or overweight with related health conditions.

Rybelsus is an oral formulation used for diabetes treatment.

Another major drug in the family is liraglutide.

Victoza is approved for type 2 diabetes.

Saxenda is approved for chronic weight management.

A newer medication, tirzepatide, occupies a slightly different scientific category. Tirzepatide activates both GLP-1 receptors and a second metabolic pathway known as GIP, or glucose-dependent insulinotropic polypeptide.

Because of this dual action, tirzepatide is often described as a dual incretin agonist rather than a pure GLP-1 agonist.

Tirzepatide appears in two widely known medications.

Mounjaro is approved for type 2 diabetes.

Zepbound is approved for chronic weight management.

Each of these medications interacts with the body’s metabolic signaling systems in ways that extend beyond simple appetite control. Yet it is important to recognize that their regulatory approval in the United States remains focused on specific medical conditions.

What These Drugs Are Actually Approved to Treat

The public narrative surrounding GLP-1 drugs often implies that they were designed primarily for weight loss. In reality, the earliest approvals focused on diabetes management.

The first GLP-1 receptor agonists were introduced to improve glycemic control in individuals with type 2 diabetes. By enhancing insulin secretion and moderating blood glucose spikes after meals, these medications offered an alternative to older diabetes treatments that sometimes carried higher risks of hypoglycemia.

During clinical trials for diabetes treatment, researchers began noticing something unexpected. Many patients taking GLP-1 medications experienced significant reductions in body weight.

This observation led to new clinical trials focusing specifically on obesity treatment. Those studies ultimately resulted in FDA approval of medications like Wegovy and Saxenda for chronic weight management.

Over time, the list of approved uses expanded again as additional benefits became apparent during long-term trials.

Semaglutide has been approved to reduce the risk of major cardiovascular events in certain adults with obesity or overweight who already have established cardiovascular disease. Tirzepatide received approval for treatment of moderate to severe obstructive sleep apnea in adults with obesity. More recently, semaglutide has also received approval for treatment of metabolic dysfunction-associated steatohepatitis, commonly known as MASH, in patients with liver fibrosis.

These expanding indications demonstrate something important: some of the effects originally described as “side benefits” of GLP-1 therapy are now recognized as legitimate therapeutic targets.

Yet none of these approvals involve addiction treatment, psychiatric conditions, or behavioral disorders. Those discussions remain firmly within the realm of ongoing research.

How the Cultural Explosion Began

If the science behind GLP-1 medications has been developing gradually for two decades, why did the public conversation erupt so suddenly?

Several forces collided at roughly the same moment.

First, the weight-loss results seen in large semaglutide trials were unusually strong compared with older obesity medications. In some studies, participants lost an average of fifteen percent or more of their body weight. That level of weight reduction approaches the results typically associated with bariatric surgery.

Second, celebrity culture accelerated awareness. High-profile public figures openly discussed their experiences with the medications, often focusing on dramatic weight loss rather than the broader metabolic context in which the drugs were developed.

Third, social media platforms amplified anecdotal experiences. TikTok videos, podcasts, and influencer testimonials rapidly spread claims about the medications’ potential to curb cravings for food, alcohol, and other substances.

Finally, pharmaceutical marketing and media coverage helped transform a medical treatment into a cultural phenomenon. News outlets frequently framed GLP-1 medications as a “game changer,” a phrase that often signals the early stages of hype in health reporting.

The result was a perfect storm of attention. Demand surged so quickly that pharmacies across the United States began reporting shortages of several GLP-1 medications.

The Rise of the Shortage Economy

As demand exploded, the supply chain struggled to keep pace. By 2023 and 2024, many pharmacies reported difficulty obtaining semaglutide and tirzepatide products. Patients with diabetes sometimes found themselves competing for medications that had originally been developed to treat their condition.

Shortages created a secondary market that raised serious safety concerns. Compounding pharmacies began producing versions of GLP-1 medications, sometimes using salt forms of semaglutide that had not undergone the same regulatory scrutiny as FDA-approved products.

The FDA issued warnings about unapproved GLP-1 formulations, counterfeit versions of Ozempic, and dosing errors linked to improperly compounded medications.

This period revealed an uncomfortable reality about American healthcare culture. When a treatment becomes fashionable, demand can quickly outstrip both regulatory safeguards and scientific caution.

The Temptation of a Universal Solution

The surge of interest in GLP-1 drugs soon extended beyond weight loss. Patients began reporting unexpected changes in behavior.

Some individuals described reduced interest in alcohol.

Others reported diminished cravings for cigarettes or recreational drugs.

Some claimed improvements in impulse control around shopping, gambling, or compulsive eating.

These anecdotes sparked a wave of speculation among researchers. If GLP-1 signaling influences appetite and satiety through the brain’s reward systems, could the same pathways also affect other forms of craving?

That question lies at the center of the scientific investigation now unfolding.

It is also the question that demands the most caution.

The human brain’s reward circuitry is extraordinarily complex. Dopamine signaling, cue reactivity, habit formation, and emotional regulation interact in ways that are still not fully understood. Observing a behavioral change during treatment does not automatically reveal the mechanism responsible for that change.

Weight loss itself can improve mood, sleep, and metabolic health. Those improvements might indirectly influence behaviors like alcohol consumption or emotional eating. Distinguishing between direct neurological effects and indirect lifestyle changes requires carefully controlled clinical trials.

At present, that work is still underway.

Why Skepticism Matters

In the modern media environment, scientific nuance rarely travels as quickly as a bold headline. Once a narrative takes hold, it becomes difficult to correct misunderstandings without sounding dismissive or cynical.

Yet skepticism does not mean rejecting the possibility of genuine discovery. It means recognizing that early signals must be tested rigorously before becoming medical advice.

The history of medicine contains many examples of promising early findings that later proved incomplete or misleading. It also contains examples of discoveries that initially seemed improbable but eventually transformed entire fields of treatment.

GLP-1 drugs may ultimately fall somewhere between those extremes.

The emerging research on craving, addiction, and behavioral regulation deserves serious attention. At the same time, the speed with which public conversation has expanded beyond the available evidence should give thoughtful observers pause.

The Larger Question Ahead

For the rest of this series, I will focus on a single question that has begun to appear in scientific literature.

Are GLP-1 drugs revealing something fundamental about how the brain processes craving and reward?

If the answer turns out to be yes, the implications could extend far beyond weight management. Addiction medicine, psychiatry, and behavioral science might all gain new insights into the biological foundations of compulsive behavior.

Yet if the current excitement proves premature, we may instead be witnessing another familiar cycle in health culture: a promising treatment inflated by enthusiasm before the evidence has matured.

The only way to determine which possibility is closer to the truth is to examine the research carefully.

That is where the next part of this series begins.

The strongest evidence emerging outside of weight loss involves a phenomenon many addiction researchers have been studying for decades: the biology of craving.

And if the early signals are correct, those discoveries could reshape how medicine thinks about addiction itself.